Neuropsychiatric systemic lupus erythematosus (NPSLE) is one of the most difficult manifestations of lupus to diagnose. Measurement of serum brain antibodies has contributed to early diagnosis and management of NPSLE before development of a debilitating disease. We aimed to assess the value of serum anti-ganglioside M1 antibodies in prediction of NPSLE, in comparison to other antibodies used in routine laboratory diagnosis of NPSLE. In addition, we are the first to study the relationship between these antibodies and cognitive function in lupus patients. Serum anti-ganglioside M1, anti-ribosomal P protein and anti-cardiolipin antibodies were measured in 30 lupus patients without clinical evidence of NPSLE, aged 8-16 years, and 30 healthy matchedsubjects. Patients were followed-up clinically by monthly neuropsychiatric evaluation and assessment of cognitive function for 12 months. Twelve patients developed neuropsychiatric manifestations during followup. Of those patients, 83.3%, 50% and 16.7% were seropositive for anti-ganglioside M1, anti-ribosomal P and anti-cardiolipin antibodies, respectively at the time of initial evaluation before clinical presentation of NPSLE. There was a significant positive association between anti-ganglioside seropositivity and cognitive dysfunction (P b 0.001). In addition, anti-ganglioside seropositivity had a significant risk for association with cognitive dysfunction (odds ratio: 36; 95% CI: 4.3-302.8). Conclusions: Serum anti-ganglioside M1 antibodies had a higher predictive value for NPSLE than other antibodies used in routine laboratory diagnosis of this disease. Thus, they may be reliable parameters for early diagnosis and management of NPSLE before clinical manifestations ensue. In addition, anti-ganglioside M1 antibodies may play a role in cognitive dysfunction found in some lupus patients.
Introduction
Involvement of the nervous system in systemic lupus erythematosus (SLE) encompasses a wide variety of neurologic and psychiatric manifestations. These manifestations vary widely from life threatening presentation, such as transverse myelitis or stroke to subtle and subclinical abnormalities in neurocognitive function such as memory, intellect and learning (Sanna et al., 2003) . Neuropsychiatric systemic lupus erythematosus (NPSLE) includes the neurologic syndromes of the central, peripheral and autonomic nervous systems and the psychiatric syndromes observed in patients with SLE in which other causes have been excluded (Nived et al., 2003) .
The American College of Rheumatology ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) has produced a standard nomenclature and a set of 19 case definitions for NPSLE (Sibbitt et al., 2002; Hanly et al., 2004) . The commonest manifestations of NPSLE include cognitive dysfunction, acute confusional states, anxiety disorder, mood disorder and psychosis (Stojanovich et al., 2007) . Cognitive dysfunction (memory, attention, language, concept formation, problem solving, executive and visuospatial dysfunctions) is one of the most frequent manifestations of NPSLE resulting in a significant impact on their ability to function (Sibbitt et al., 2002) . It reflects an immune-mediated compromise of the underlying neuronal substrate rather than the non-specific effects of chronic illnesses or its treatment (Carbotte et al., 1995; Khedr et al., 2001) . NPSLE may be the first indications of SLE and can be present when SLE disease activity cannot be detected in other organ systems (Kajs-Wyllie, 2002; Hanly et al., 2009) . CNS involvement indicates an increased risk for nervous system damage and premature death and it ranks second to renal failure as a cause of death in SLE (Karassa et al., 2000) .
It is paramount in the diagnosis of any patient with NPSLE that secondary causes (e.g. infection, electrolyte imbalance, hypertension, uraemia and medications) are excluded and treated appropriately as they are twice as common as primary NPSLE (Teh, 2003) . The accurate diagnosis of primary NPSLE and its differentiation from secondary central nervous system involvement are challenging (Yoshida et al., 2007) . NPSLE is one of the most difficult manifestations of lupus to diagnose that requires a careful clinical and laboratory assessment (Teh, 2003) . The major advances in laboratory and neuroimaging studies may contribute to an earlier and a more specific diagnosis of nervous involvement in SLE for a better clinical care before the development of a debilitating disease (Kajs-Wyllie, 2002; Castellino et al., 2008; Efthimiou and Blanco, 2009 ). In addition, testing for brain antibodies may help in distinguishing between primary and secondary NPSLE (Tzioufas et al., 2000) .
Testing for anti-ribosomal P and anti-phospholipid antibodies, which have been associated with some neurological manifestations of SLE, are currently routinely available in most diagnostic laboratories. However, inconsistencies in their prevalence and clinical correlations have become an obstacle to their use as diagnostic markers of the disease (Tzioufas et al., 2000; Greenwood et al., 2002) .
Gangliosides are a family of sialylated glycosphingolipids expressed in the outer leaflet of the plasma membrane of the cells of all vertebrates. They are particularly abundant in the nervous system, in particular at synapses and they are, to some extent, involved in neurotransmission at the neuromuscular junction (Ariga et al., 2008; Zitman et al., 2008 Zitman et al., , 2009 Zitman et al., , 2010 . Gangliosides are thought to play important roles in memory formation, neuritogenesis, synaptic transmission, and other neural functions (Kato and Hatanaka, 2008; Sugiura et al., 2008) . The administration of exogenous gangliosides seems to improve nerve regeneration (Ribeiro et al., 2008) . Ganglioside M1 is the most abundant ganglioside in neural membranes. It may be an autoantigen through the galactose-galactosamine part of its sugar moiety (Plomp and Willison, 2009 ). In humans, gangliosides elicit a T-cell independent IgM response (Ravindranath et al., 2005) .
In immune-mediated neurological disorders, various antibodies against neuronal tissues have been discovered. Some of these antibodies have been found to correlate with the pathomechanism of the disease (Watanabe and Arimura, 2008) . The key to establish an immunopathogenic role for a brain autoantibody is to determine its effects on specific brain functions (Greenwood et al., 2002) .
With this background, we aimed to assess the value of serum antiganglioside M1 antibodies in the prediction of NPSLE, in comparison to antibodies used in routine laboratory diagnosis of NPSLE. The relationship between these antibodies and cognitive function was also studied.
Materials and methods

Study population
This case-control, follow-up study was conducted over a period of 15 months from the beginning of September 2008 to the end of November 2009. It included 30 patients (24 females and 6 males) with SLE diagnosed according to the American Rheumatism Association Revised Criteria for diagnosis of SLE (Hochberg, 1997) . Patients were recruited from the Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt. Their ages ranged between 8 and 16 years with a mean age of 11.6 ± 2.7 years. All lupus patients had no NPSLE according to the absence of clinical evidence of nervous system involvement, based on the 19 standard neuropsychiatric syndromes in SLE defined by the ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999). Patients with cognitive dysfunction or neuropsychiatric manifestations were excluded from the study.
In addition, all lupus patients were receiving oral prednisolone (0.5-2 mg/kg/day) either alone (n = 24) or in combination with other immunosuppressive drugs such as intravenous pulse cyclophosphamide (n = 6). Patients were followed-up clinically by monthly neuropsychiatric examination and assessment of cognitive function for 12 months.
Patients were studied in comparison to 30 age-and sex-matched apparently healthy children recruited from the Outpatients Clinic,
Children's Hospital, Ain Shams University, serving as controls. They were the sibs of the children attending this clinic because of a minor illness (e.g. common cold, tonsillitis, acute bronchitis, … etc). The control children had no clinical findings suggesting immune or neuropsychiatric disorders. They were 24 females and 6 males. Their ages ranged between 8 and 16 years with a mean age of 11.5 ± 2.4 years.
An informed written consent was signed by the parents or the caregivers of each studied subject before enrollment in the study.
Study measurements
Clinical evaluation of lupus patients
This was based on clinical history taking from caregivers, reviewing follow-up sheets and clinical examination. Special emphasis was done on assessment of disease activity, by using systemic lupus erythematosus disease activity index "SLEDAI" (Bombardier et al., 1992) , neurological manifestations (e.g. convulsions, motor or sensory changes, transient ischemic attacks "TIATs", involuntary movements, headache, … etc) and psychiatric examination using minikid schedule (Sheehan et al., 1998) .
Assessment of cognitive function
Cognitive function (memory, attention, language, concept formation, problem solving, executive and visuospatial functions) was assessed with age-appropriate, translated and validated psychometric instruments that were administered by well-trained psychologists using a set of Arabic norms (Meleka and Ismail, 1999 ) for a translated Wechsler Intelligence Scale for Children, 3rd edition "WISC-III" (Wechsler, 1991) . This scale is the most commonly used test to assess cognitive function in the children. Three global measures were examined in the present study. The verbal intelligence quotient (IQ) is derived from different subtests including information, similarities, arithmetic, comprehension, vocabulary and digit span. The performance IQ is derived from different subtests including picture completion, block design, picture arrangement, object assembly and digit symbol. The full-scale IQ is the sum of the verbal and performance IQ. The individual subtests may be particularly useful because each depends on a variety of capabilities and dysfunction of any one could result in a low score on one of the global measures. Cognitive dysfunction is diagnosed when the difference between verbal and performance IQ is more than 15 and/or the result of one or more of the individual subtests is below 7 and/or the full-scale IQ is below 70.
Measurement of serum anti-ganglioside M1 IgM and IgG antibodies
Measurement of serum anti-ganglioside M1 IgM and IgG antibodies was done by ELISA for determining the levels of anti-ganglioside M1 IgM and IgG antibodies in biological samples (Buhlmann Laboratories AG, Baselstrasse 55, CH-4124 Schonenbuch, Switzerland). Briefly, antiganglioside M1 antibodies from patients' sera, calibrators and controls were incubated with ganglioside M1 coated onto microtitre wells. After the removal of unreacted material by a washing step, horseradish peroxidase-labeled antibodies against human IgM and IgG were added to wells. After the second washing step, the enzyme substrate tetramethylbenzidin was added to the wells. Blue color developed in proportion to the amount of anti-ganglioside M1 IgM and IgG antibodies bound in the initial step. The reaction was terminated by the addition of stop solution and the color turned from blue to yellow. The absorbance was measured in a microtitre plate reader at a wave length of 450 nm. Results were calculated by using a standard curve where the absorbance of calibrators was plotted versus their corresponding titre units on a lin/ log graph paper. The lower detection limits for anti-ganglioside GM1 IgG and IgM isotypes are 59 BTU and 52 BTU, respectively (Morton, 2005) .
Measurement of serum total IgG and IgM anti-ribosomal P protein antibodies
Serum total IgG and IgM anti-ribosomal P protein antibodies were measured by ELISA using ribosomal P peptide-bovine serum albumin conjugate as an antigen (Nunc immuno module F8 maxisorp; Nunc. Roskilde, Denmark). The lower detection limit for anti-ribosomal P protein antibodies is 1.0 U/dl (Yoshio et al., 1995) .
Routine laboratory investigations of SLE
Routine laboratory investigations of SLE include complete blood picture, first hour erythrocyte sedimentation rate (Westergren method), routine microscopic urine analysis, 24 hour urine protein, serum and urinary creatinine, corrected creatinine clearance, serum complement 3, ANA (immuno-fluorescence technique), anti ds-DNA (ELISA) and anti-cardiolipin antibodies (ELISA).
Statistical analysis
The results were analyzed by commercially available software package (Statview, Abacus concepts, inc., Berkley, CA, USA). The data were non-parametric, thus they were presented as median and interquartile range (IQR), which is the difference between the 25th and 75th percentiles. Mann-Whitney test was used for comparison between non-parametric data. Spearman's correlation coefficient "r" was used to determine the relationship between different quantitative variables. Chi-square (χ 2 ) test was used for comparison between qualitative variables of the studied groups. A probability (P) of less than 0.05 was considered significant. Risk estimation was done to calculate the odds ratio and its 95% confidence interval (CI). CI is significant when the value of 1 is not included in its range. Patients were considered to be seropositive for either anti-ganglioside M1 IgM or IgG antibodies if the levels of these antibodies were above the calculated highest cut-off value (the 95th percentile of the control values, which was 800 Buhlmann titre unit (BTU) for both antibodies).
Results
The characteristics of the study subjects are shown in Table 1 . During follow-up, 12 patients developed clinical evidence of NPSLE. Out of those patients, 2 had cognitive dysfunction and 2 had neuropsychiatric manifestations (focal convulsions, severe depression and moderate anxiety in one patient and TIATs, moderate depression and signs of pyramidal tract lesion in the other patient). The remaining 8 patients had both clinical evidence of cognitive dysfunction and neuropsychiatric manifestations (signs of pyramidal tract lesion in 2 patients, TIATs and moderate depression in another 2 patients, sensory changes suggestive of peripheral neuritis and severe depression in another patient, lower motor cranial nerve lesions localized to brain stem and severe depression in one patient, signs of pyramidal tract lesion with severe anxiety in another patient and focal convulsions, moderate depression and lower motor cranial nerve lesions localized to brain stem in the remaining patient).
Serum anti-ganglioside M1 antibodies in lupus patients and healthy controls
Lupus patients had significantly higher serum anti-ganglioside M1 IgM antibodies than healthy controls (P b 0.001). In contrast, lupus patients and healthy controls had comparable values of serum antiganglioside M1 IgG antibodies (P = 0.4) ( Table 2) .
Seropositivity of anti-ganglioside M1 IgM antibodies was found in 33.3% (10/30) of lupus patients, while seropositivity of antiganglioside M1 IgG antibodies was found in 13.3% (4/30) of those patients. In addition, 13.3% (4/30) of lupus patients were seropositive for both anti-ganglioside M1 isotypes (IgM and IgG).
On the other hand, patients who developed clinical evidence of NPSLE during follow-up (n = 12) had significantly higher serum antiganglioside M1 IgM antibodies than patients without such evidence (n = 18), P b 0.001. In contrast, patients with and without NPSLE had comparable values of serum anti-ganglioside M1 IgG antibodies (P = 0.1) ( Table 2) .
Serum anti-ribosomal P and anti-cardiolipin antibodies in lupus patients and healthy controls
Lupus patients had significantly higher serum anti-ribosomal P and anti-cardiolipin IgM antibodies than healthy controls (P b 0.001 and P b 0.001, respectively). In contrast, lupus patients and healthy controls had comparable values of serum anti-cardiolipin IgG antibodies (P = 0.5) ( Table 3) .
Seropositivity of anti-ribosomal P antibodies was found in 20% (6/ 30) of lupus patients. In addition, 16.7% (5/30) and 13.3% (4/30) of those patients were seropositive for anti-cardiolipin IgM and IgG antibodies, respectively. Moreover, 6.67% (2/30) of lupus patients were seropositive for both anti-cardiolipin isotypes (IgM and IgG).
On the other hand, patients with clinical evidence of NPSLE had significantly higher serum anti-ribosomal P antibodies than patients without such evidence, P b 0.001. In contrast, patients with and without NPSLE had comparable values of serum anti-cardiolipin IgM and IgG antibodies (P = 0.4 and P = 0.1, respectively) ( Table 3) . 
The role of serum antibodies in early prediction of NPSLE
At the time of initial evaluation, before the clinical presentation of NPSLE, seropositivity of anti-ganglioside M1, anti-ribosomal P and anti-cardiolipin antibodies was found in 83.3%, 50% and 16.7%, respectively of patients who developed clinical evidence of NPSLE, later on, during follow-up. Seropositivity for both anti-ganglioside M1 and anti-ribosomal P antibodies was detected in 33.3% of those patients (Table 4) . Interestingly, all patients who developed clinical evidence of NPSLE, during follow-up, were seropositive for at least one of the studied antibodies.
In contrast, none of the 18 patients who had no clinical evidence of NPSLE was seropositive for either anti-ganglioside M1 or antiribosomal P antibodies. On the other hand, 16.7% of those patients were seropositive for anti-cardiolipin antibodies (Table 4) .
Cognitive function in lupus patients and healthy controls
Clinical evidence of cognitive dysfunction was detected in 10 lupus patients (33.3%) during follow-up. Thus, 83.3% (10/12) of lupus patients with clinical evidence of NPSLE had cognitive dysfunction.
The difference between verbal and performance IQ was more than 15 in one patient. Another 3 patients had deficits in one or more of the subsets of verbal IQ (arithmetic in one and arithmetic and digit span in the remaining 2 patients). Two more patients had deficits in one or more of the subsets of performance IQ (block design in one patient and both block design and digit symbol in the remaining patient). Another 2 patients had deficits in one or more of the subsets of both verbal and performance IQ (arithmetic and digit symbol in one patient and digit span and block design in the remaining patient). The remaining 2 patients had full-scale IQ below 70 and deficits in one or more of the subsets of verbal and/or performance IQ (arithmetic, digit span and digit symbol in one patient and arithmetic, digit span and block design in the remaining patient) (Table 5) . Thus, deficits in arithmetic, digit span, block design and digit symbol subsets of verbal and performance IQ were found in 6, 5, 4 and 3 children with cognitive dysfunction, respectively.
Clinical evidence of cognitive dysfunction was found in only 6.7% (2/30) of healthy children. One child had deficits in arithmetic and digit span and the other one had deficits in arithmetic and block design. The frequency of cognitive dysfunction was significantly higher in lupus patients than healthy children, P b 0.001.
Association between cognitive dysfunction and the studied serum antibodies in lupus patients
There was a significant positive association between anti-ganglioside M1 seropositivity and cognitive dysfunction as the frequency of anti-ganglioside M1 seropositivity was significantly higher in patients with cognitive dysfunction than patients with normal cognitive function (P b 0.001). In addition, anti-ganglioside seropositivity had a significant risk for association with cognitive dysfunction (odds ratio: 36; 95% CI: 4.3-302.8) (Table 6 ). Median ( Seropositivity for both anti-ribosomal P and anti-cardiolipin IgM antibodies (n = 2) 2/12 (16.7%) 0 NPSLE, neuropsychiatric systemic lupus erythematosus.
Table 5
Clinical evidence of cognitive dysfunction and the time of its diagnosis in the 10 lupus patients during the 12 month follow-up.
Lupus patients with cognitive dysfunction
Clinical evidence of cognitive dysfunction and the time of their diagnosis during the 12 month follow-up Deficits in the subsets of verbal IQ Deficits in the subsets of performance IQ Full-scale IQ below 70
1 The difference between verbal and performance IQ was more than 15 (after 6 months) 2 Arithmetic (after 2 months) 3 Arithmetic (after 2 months) Digit span (after 5 months) 4 Arithmetic (after 3 months) Digit span (after 4 months) 5
Block design (after one month) 6
Block design (after 2 months) Digit symbol (after 9 months) 7 Arithmetic (after 3 months) Digit symbol (after 4 months) 8
Digit span (after 5 months) Block design (after 3 months) 9
Arithmetic (after 2 months) Digit symbol (after 8 months) After 9 months Digit span (after 6 months) 10 Arithmetic (after 4 months) Block design (after 4 months) After 11 months Digit span (after 7 months)
Although the frequency of anti-ribosomal P seropositivity was significantly higher in patients with cognitive dysfunction than patients with normal cognitive function, this difference did not reach statistical significance (P = 0.053). On the other hand, there was a non-significant difference between the frequency of anti-cardiolipin seropositivity of patients with and without cognitive dysfunction (P = 0.48) ( Table 6 ).
3.6. Association between disease activity, as assessed by SLEDAI, and both clinical evidence of NPSLE and seropositivity of the studied serum antibodies in lupus patients
There was a non-significant statistical difference between SLEDAI of patients with and without clinical evidence of NPSLE (P = 0.2) and seropositivity of anti-ganglioside M1, anti-ribosomal P and anticardiolipin antibodies (P = 0.7, P = 0.7 and P = 0.6, respectively) ( Table 7 ). In addition, serum anti-ganglioside M1 IgG and IgM, antiribosomal P and anti-cardiolipin IgG and IgM antibodies did not correlate significantly to SLEDAI of lupus patients (P = 0.7, P = 0.6, P = 0.9, P = 0.2 and P = 0.4, respectively).
3.7. Association between seropositivity of both ANA and anti ds-DNA and both clinical evidence of NPSLE and seropositivity of the studied serum antibodies in lupus patients There were non-significant associations between seropositivity of both ANA and anti ds-DNA and clinical evidence of NPSLE (P = 0.3 and P = 0.4, respectively). Similarly, ANA and anti ds-DNA had no significant associations with seropositivity of anti-ganglioside M1 (P = 0.3 and P = 0.4, respectively), anti-ribosomal P (P = 0.2 and P = 0.7, respectively) and anti-cardiolipin antibodies (P = 0.8 and P = 0.7, respectively) ( Table 8 ).
Discussion
The diagnosis of NPSLE is based on the combination of clinical features and immunoserological tests (Hermosillo-Romo and Brey, 2002 ). In the current study, the frequency of NPSLE was 40%. Previous estimates of the prevalence of NPSLE ranged from 17 to 75% reflecting variable diagnostic criteria and heterogeneity in the clinical populations studied (Colasanti et al., 2009) .
The pathogenic mechanisms involved in primary NPSLE are obscure. Proposed mechanisms include antibody-mediated neuronal cell injury or dysfunction and vascular occlusion due to vasculopathy, vasculitis, leukoaggregation or thrombosis (Sany-Choel, 2003) . The development of organ-associated autoantibodies generally precedes the appearance of their associated clinical features in lupus patients (Heinlen et al., 2007) . Distinct antibodies detectable in serum of lupus patients are associated with the presence of neuropsychiatric disorders. These antibodies may have a pathogenic relevance in NPSLE or they may be merely an epiphenomenon (Colasanti et al., 2009 ).
Indeed, due to their location in the nervous system, gangliosides could be a target molecule in the complex autoimmune response and thus, may play a pathogenic role in NPSLE (Galaezzi et al., 2000) . In the present study, lupus patients had significantly higher serum antiganglioside M1 IgM antibodies than healthy controls (P b 0.001). The current study also revealed seropositivity of anti-ganglioside M1 antibodies in 33.3% (10/30) of lupus patients. Studies regarding serum anti-ganglioside M1 IgM antibodies in SLE are very few. A previous study reported anti-ganglioside M1 seropositivity in 10 out of 60 adult patients with SLE (16.6%) and the incidence of these antibodies was not significantly higher in lupus patients with symptoms related to the nervous system than in patients without neurological involvement (Martinez et al., 1992) . Another study conducted on 448 with SLE enrolled in 8 centers from 6 European countries reported seropositivity of anti-ganglioside M1 antibodies in 15.5% of the studied patients and both anti-ganglioside M1 isotypes were associated with neuropsychiatric manifestations (Galaezzi et al., 2000) . The discrepancies between the results of these studies may be attributable to the variations in the number of the studied lupus patients, their ages and the frequency of the neuropsychiatric manifestations in these patients. As the number of the studied (25) NPSLE, neuropsychiatric systemic lupus erythematosus. SLEDAI, systemic lupus erythematosus disease activity index.
Table 8
Association between seropositivity of ANA and anti ds-DNA and both clinical evidence of NPSLE and seropositivity of the studied serum antibodies.
ANA positive ANA negative χ 2 Anti ds-DNA positive Anti ds-DNA negative χ 2 (n = 25) (n = 5) (P) (n = 20) (n = 10) patients is limited in our study, another study, on a large scale, to investigate the frequency of anti-ganglioside M1 antibodies in Egyptian pediatric lupus patients and to study their relations to neuropsychiatric findings is recommended. The reason behind this seropositivity is not fully understood. It is speculated that this autoimmune reaction to neurons might be trigged by other cross-reacting antigens in the environment resulting in the release of neuronal antigens which through the activation of inflammatory cells, may result in autoimmune reactions in genetically susceptible individuals. The following chain of events may lead to the production of brain antibodies. First: pre-existing autoreactive T-cells are generated by molecular mimicry as a result of contact with dietary proteins or infectious agents antigens, with sequence homologies with autoantigens. Second: toxic chemicals (such as bacterial enterotoxins, and heavy metals), may increase adhesion molecules on brain endothelial cells. Third: pre-existing autoreactive T-cells may transmigrate across the blood-brain barrier (BBB) and induce activation of local antigen-presenting cells (such as microglia and astrocytes). Lastly: production of cytokines by T-helper-1 autoreactive antigen-presenting cells may result in oligodendrocyte damage and demyelination. These events result in the release of antigens from neurofilaments that enter the circulation producing immune reactions due to the formation of plasma cells which produce antibodies against neuron-specific antigens. These antibodies may cross the BBB and combine with brain tissue antigens forming immune complexes, thus further damaging the neurological tissue (Vojdani et al., 2002) .
Tests for anti-ganglioside antibodies remain highly specialized, whereas tests for ribosomal P antibodies and for anti-phospholipid antibodies are currently routinely available in most diagnostic laboratories (Greenwood et al., 2002 ). In the current study, lupus patients had significantly higher serum anti-ribosomal P antibodies than healthy controls (P b 0.001). Seropositivity of anti-ribosomal P antibodies was found in 20% (6/30) of our lupus patients. Other investigators reported positivity of anti-ribosomal P antibodies in 21.9% (7/32) of lupus patients, all of whom had one or more NPSLE syndromes. These investigators also reported that anti-ribosomal P antibodies were specific, but not sensitive, for NPSLE (Abdel-Nasser et al., 2008) . The association of anti-ribosomal P antibodies with psychiatric or neurological manifestations has been proposed, but remains controversial (Caponi et al., 2007) .
Antibodies have long been suspected to play a central role in the pathogenesis of NPSLE (Greenwood et al., 2002) . This argument was supported by our finding of a significant increase of serum levels of anti-ganglioside M1 IgM and anti-ribosomal P antibodies in patients with (n = 12) than those without NPSLE (n = 18) (P b 0.001). These results may indicate the possible pathogenic role of these antibodies in nervous involvement in SLE. However, it is far from clear whether autoimmunity to neuronal antigens is a consequence of the disease or actually initiates the process (Plomp and Willison, 2009) .
In the present work, of the 12 patients who developed NPSLE during follow-up, seropositivity of anti-ganglioside M1, anti-ribosomal P and anti-cardiolipin antibodies was found in 83.3%, 50% and 16.7%, respectively of those patients, meaning that anti-ganglioside M1 had a higher predictive value for NPSLE than other antibodies used in routine laboratory diagnosis of NPSLE. Interestingly, all those patients were seropositive for at least one of the studied antibodies. In contrast, none of the 18 patients without clinical evidence of NPSLE was seropositive for either anti-ganglioside M1 or anti-ribosomal P antibodies. Other researchers reported a strong correlation between anti-ganglioside IgM antibodies and neuropsychiatric manifestations. In contrast, they did not find a significant correlation between anti-cardiolipin IgM and IgG antibodies and neuropsychiatric manifestations (Costallat et al., 1990) . These investigators concluded that the analysis of anti-ganglioside IgM antibodies showed an important predictive role for neuropsychiatric manifestations in SLE and the negative test decreases the chance of the neuropsychiatric manifestations.
Thus, our findings indicate that serum anti-ganglioside M1 antibodies may be valuable predictors for NPSLE and when these antibodies were measured with anti-ribosomal P antibodies, the prediction value of both antibodies for NPSLE was 100%. Further studies, on a large scale, regarding the predictive value of serum antiganglioside M1 antibodies for NPSLE are warranted.
Cognitive dysfunction is one of the most frequent manifestations of NPSLE that have a significant impact on their ability to function (Sibbitt et al., 2002) . In the present study, clinical evidence of cognitive dysfunction was found in 33.3% of all lupus patients and in 83.3% of lupus with clinical evidence of NPSLE during follow-up. A recent study conducted on a group of Egyptian children and adolescents with SLE reported cognitive dysfunction in 68.2% (15/22) of patients with clinical evidence of NPSLE (Mostafa et al., 2009 ).
There was a consistent finding in this study that deficits were found on only four subtests of the verbal and performance IQ (digit span, arithmetic, digit symbol and block design). These tests are used in a clinical setting to show abilities in working memory and attention (digit span and arithmetic), processing speed (digit symbol) and perceptual reasoning (block design). Thus, NPSLE may result in the lack of attention and concentration, both of which may result in poor scholastic achievement. We could not trace data in literature regarding which subtests of verbal and performance IQ show deficits in lupus children to compare our results.
The key to establish an immunopathogenic role for a brain autoantibody is to determine its effects on specific brain functions (Greenwood et al., 2002) . Thus, this study was the first to investigate the relationship between seropositivity of anti-ganglioside antibodies and cognitive function. There was a significant positive association between anti-ganglioside M1 seropositivity and cognitive dysfunction as the frequency of seropositivity of these antibodies was significantly higher in patients with cognitive dysfunction than patients with normal cognitive function (P b 0.001). In addition, seropositivity of anti-ganglioside M1 antibodies had a significant risk for association with cognitive dysfunction (odds ratio = 36; 95% CI = 4.3-302.8). Thus, the relationship between anti-ganglioside M1 antibodies and cognitive dysfunction may be a causal one in which these antibodies might be playing a role in the pathogenesis of brain damage with subsequent cognitive dysfunction. Little is known about the mechanisms and relevance of cognitive dysfunction in lupus patients who never displayed major neuropsychiatric manifestations (Olazarán et al., 2009) . Some investigators demonstrated that cognitive dysfunction in SLE reflects an immune-mediated compromise of an underlying neural substrate rather than the non-specific effects of disease activity, chronic illness or its treatment (Carbotte et al., 1995) .
Whenever a lupus patient develops central or peripheral nervous system manifestations, evaluation for systemic disease activity is important to determine if the activation of the systemic disease is also occurring (Navarrete and Brey, 2000) . In the present study, there was a non-significant relationship between disease activity assessed by SLEDAI and both clinical evidence of NPSLE and seropositivity of the studied antibodies. NPSLE may occur as an isolated event without other systemic signs of disease activity (Carbotte et al., 1995) .
In addition, there was a non-significant association between seropositivity of both ANA and anti ds-DNA and clinical evidence of NPSLE. Similarly, ANA and anti ds-DNA had no significant association with seropositivity of the studied antibodies, meaning that serum ANA and anti ds-DNA are not reliable immumoserological markers of diagnosis of NPSLE. A previous study also demonstrated the absence of significant associations between anti-ganglioside M1 antibodies and ANA, anti ds-DNA and anti-cardiolipin antibodies (Galaezzi et al., 2000) .
In conclusion, serum anti-ganglioside M1 antibodies have a higher predictive value for NPSLE than other antibodies used in routine laboratory diagnosis of this disease. Thus, these antibodies may be reliable parameters for the prediction of NPSLE, before clinical manifestations ensue, especially when they are measured with antiribosomal P antibodies that are used in routine laboratory diagnosis of NPSLE. In addition, anti-ganglioside M1 antibodies may play a role in cognitive dysfunction that is found in some lupus patients. Further studies, on a large scale, are warranted to evaluate the predictive value of these antibodies in NPSLE. If this could be proved, this may highlight the value of adding these parameters to the routine list of investigations of SLE for early diagnosis and management of NPSLE before the development of a debilitating disease.
